Search Results - "Treitel, Michelle"

Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir by Hulskotte, Ellen G. J., Feng, Hwa-Ping, Xuan, Fengjuan, van Zutven, Marga G. J. A., Treitel, Michelle A., Hughes, Eric A., O'Mara, Edward, Youngberg, Stephen P., Wagner, John A., Butterton, Joan R.

“…Background. Boceprevir represents a new treatment option for hepatitis C (HCV)—infected patients, including those with HCV/human immunodeficiency virus…”
Get full text

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients by de Bruijne, Joep, Bergmann, Jilling F., Reesink, Henk W., Weegink, Christine J., Molenkamp, Richard, Schinkel, Janke, Tong, Xiao, Li, Jing, Treitel, Michelle A., Hughes, Eric A., van Lier, Jan Jaap, van Vliet, Andre A., Janssen, Harry L. A., de Knegt, Robert J.

“…Narlaprevir (SCH 900518) is a potent inhibitor of the hepatitis C virus (HCV) nonstructural protein 3 serine protease that is primarily metabolized by the…”
Get full text

Repression by SSN6-TUP1 is directed by MIG1, a repressor/activator protein by Treitel, M.A. (Columbia University, New York, NY.), Carlson, M

“…The SSN6-TUP1 protein complex represses transcription of diversely regulated genes in the yeast Saccharomyces cerevisiae. Here we present evidence that MIG1, a…”
Get full text

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection by Rodriguez-Torres, Maribel, Läwitz, Eric, Yangco, Bienvenido, Jeffers, Lennox, Han, Steven-Huy, Thuluvath, Paul J, Rustgi, Vinod, Harrison, Stephen, Ghalib, Reem, Vierling, John M, Luketic, Velimir, Zamor, Philippe J, Ravendhran, Natarajan, Morgan, Timothy R, Pearlman, Brian, O’Brien, Christopher, Khallafi, Hicham, Pyrsopoulos, Nikolaos, Kong, George, McPhee, Fiona, Yin, Philip D, Hughes, Eric, Treitel, Michelle

“…AbstractBackground. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with…”
Get full text

836 Sustained Virologic Response (SVR) in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Retreatment With Boceprevir (BOC) + PR: the Provide Study Interim Results by Vierling, John M, Davis, Mitchell N, Flamm, Steven L, Gordon, Stuart C, Lawitz, Eric J, Yoshida, Eric M, Galati, Joseph, Luketic, Velimir A, McCone, Jonathan, Jacobson, Ira M, Marcellin, Patrick, Muir, Andrew J, Poordad, Fred, Pedicone, Lisa D, Deng, Weiping, Treitel, Michelle A, Wahl, Janice, Bronowicki, Jean-Pierre

Get full text

Snf1 Protein Kinase Regulates Phosphorylation of the Mig1 Repressor in Saccharomyces cerevisiae by Treitel, Michelle A., Kuchin, Sergei, Carlson, Marian

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in the Phase 3 POETYK PSO-1 and PSO-2 Trials by Blauvelt, Andrew, Korman, Neil J., Merola, Joseph F., Gooderham, Melinda, Balagula, Eugene, Vanlandingham, Rebecca, Treitel, Michelle, Wittstock, Keith, Hoyt, Kim, Banerjee, Subhashis, Desai, Seemal R.

“…Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, was efficacious and well tolerated in adults with moderate to severe plaque…”
Get full text

Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function by Treitel, Michelle, Marbury, Thomas, Preston, Richard A, Triantafyllou, Ilias, Feely, William, O'Mara, Edward, Kasserra, Claudia, Gupta, Samir, Hughes, Eric A

“…Background and Objective: Boceprevir is a novel inhibitor of the hepatitis C virus NS3 protease and was recently approved for the treatment of patients with…”
Get full text

A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin by Wei, Lai, Zhang, Mingxiang, Xu, Min, Chuang, Wan-Long, Lu, Wei, Xie, Wen, Jia, Zhansheng, Gong, Guozhong, Li, Yueqi, Bae, Si Hyun, Yang, Yong-Feng, Xie, Qing, Lin, Shumei, Chen, Xinyue, Niu, Junqi, Jia, Jidong, Garimella, Tushar, Torbeyns, Anne, McPhee, Fiona, Treitel, Michelle, Yin, Philip D., Mo, Ling

“…Background and Aim Daclatasvir plus asunaprevir has demonstrated efficacy and safety in patients with chronic hepatitis C virus genotype 1b infection. This…”
Get full text

Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function by Treitel, Michelle, Marbury, Thomas, Preston, Richard A., Triantafyllou, Ilias, Feely, William, O’Mara, Edward, Kasserra, Claudia, Gupta, Samir, Hughes, Eric A.

“…Background and Objective Boceprevir is a novel inhibitor of the hepatitis C virus NS3 protease and was recently approved for the treatment of patients with…”
Get full text

Daclatasvir/asunaprevir/beclabuvir, all‐oral, fixed‐dose combination for patients with chronic hepatitis C virus genotype 1 by Kao, Jia‐Horng, Yu, Ming‐Lung, Peng, Cheng‐Yuan, Heo, Jeong, Chu, Chi‐Jen, Chang, Ting‐Tsung, Lee, Youn‐Jae, Hu, Tsung‐Hui, Yoon, Ki Tae, Paik, Seung Woon, Lim, Young Suk, Ahn, Sang Hoon, Isakov, Vasily, McPhee, Fiona, Hu, Wenhua, Scott Swenson, Eugene, Yin, Philip D, Treitel, Michelle

“…Background and Aim This multinational (Taiwan, South Korea, Russia) phase 3 study evaluated the all‐oral, ribavirin‐free, fixed‐dose combination (DCV‐TRIO) of…”
Get full text

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection by Wei, Lai, Wang, Fu-Sheng, Zhang, Ming-Xiang, Jia, Ji-Dong, Yakovlev, Alexey A, Xie, Wen, Burnevich, Eduard, Niu, Jun-Qi, Jung, Yong Jin, Jiang, Xiang-Jun, Xu, Min, Chen, Xin-Yue, Xie, Qing, Li, Jun, Hou, Jin-Lin, Tang, Hong, Dou, Xiao-Guang, Gandhi, Yash, Hu, Wen-Hua, McPhee, Fiona, Noviello, Stephanie, Treitel, Michelle, Mo, Ling, Deng, Jun

“…To assess daclatasvir plus asunaprevir (DUAL) in treatment-naïve patients from mainland China, Russia and South Korea with hepatitis C virus (HCV) genotype 1b…”
Get full text

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3 by Silva, Marcelo O, Treitel, Michelle, Graham, Donald J, Curry, Stephanie, Frontera, Maria J, McMonagle, Patricia, Gupta, Samir, Hughes, Eric, Chase, Robert, Lahser, Fred, Barnard, Richard J.O, Howe, Anita Y.M, Howe, John A

“…Background & Aims To examine the antiviral activity of boceprevir, a hepatitis C virus (HCV) protease inhibitor, in HCV genotype (G) 2/3-infected patients…”
Get full text

Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response by Vierling, John M, Davis, Mitchell, Flamm, Steven, Gordon, Stuart C, Lawitz, Eric, Yoshida, Eric M, Galati, Joseph, Luketic, Velimir, McCone, Jonathan, Jacobson, Ira, Marcellin, Patrick, Muir, Andrew J, Poordad, Fred, Pedicone, Lisa D, Albrecht, Janice, Brass, Clifford, Howe, Anita Y.M, Colvard, Lynn Y, Helmond, Frans A, Deng, Weiping, Treitel, Michelle, Wahl, Janice, Bronowicki, Jean-Pierre

“…Background & Aims Boceprevir with peginterferon/ribavirin (BOC/PR) leads to significantly higher sustained virological response (SVR) rates in patients with…”
Get full text

Effect of Boceprevir on Red Blood Cells and Markers of Anemia in Healthy Volunteers by Kasserra, Claudia, Treitel, Michelle, Hughes, Eric A, O'Mara, Edward, Jaap van Lier, Jan

Get full text

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection by Rodriguez-Torres, Maribel, Läwitz, Eric, Yangco, Bienvenido, Jeffers, Lennox, Han, Steven-Huy, Thuluvath, Paul J, Rustgi, Vinod, Harrison, Stephen, Ghalib, Reem, Vierling, John M, Luketic, Velimir, Zamor, Philippe J, Ravendhran, Natarajan, Morgan, Timothy R, Pearlman, Brian, O'Brien, Christopher, Khallafi, Hicham, Pyrsopoulos, Nikolaos, Kong, George, McPhee, Fiona, Yin, Philip D, Hughes, Eric, Treitel, Michelle

“…Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin…”
Get full text

819Daclatasvir in Combination with Peginterferon Alfa-2a and Ribavirin for Treatment-Naive Patients with HCV Genotype 4 Infection: Phase 3 COMMAND-4 Results by Hézode, Christophe, Alric, Laurent, Brown, Ashley, Hassanein, Tarek, Rizzetto, Mario, Buti, Maria, Bourliere, Marc, Thabut, Dominique, Molina, Esther, Mcphee, Fiona, Liu, Zhaohui, Yin, Philip, Hughes, Eric, Treitel, Michelle

Get full text

Short-Term Administration of the CCR5 Antagonist Vicriviroc to Patients With HIV and HCV Coinfection Is Safe and Tolerable by Fätkenheuer, Gerd, Hoffmann, Christian, Slim, Jihad, Rouzier, Régine, Keung, Anther, Li, Jing, Treitel, Michelle, Sansone-Parsons, Angela, Kasserra, Claudia, OʼMara, Edward, Schürmann, Dirk

“…OBJECTIVE:CCR5 antagonists block HIV cell entry through competitive binding to the CCR5 receptor present on the surface of CD4 cells. The CCR5 receptor is also…”
Get full text

Functional Interdependence of the Yeast SNF2, SNF5, and SNF6 Proteins in Transcriptional Activation by Laurent, Brehon C., Treitel, Michelle A., Carlson, Marian

“…The SNF2, SNF5, and SNF6 genes of Saccharomyces cerevisiae are required for expression of a variety of differently regulated genes. Previous evidence…”
Get full text

N-Terminal Mutations Modulate Yeast SNF1 Protein Kinase Function by Estruch, F, Treitel, M. A, Yang, X, Carlson, M

“…The SNF1 protein kinase is required for expression of glucose-repressed genes in response to glucose deprivation. The SNF4 protein is physically associated…”
Get full text